⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5087405 | 1.00 | — | — | |
| SCHEMBL14754483 | 0.83 | — | — | |
| SCHEMBL27614255 | 0.83 | — | — | |
| SCHEMBL15591527 | 0.83 | — | — | |
| SCHEMBL3470193 | 0.81 | NPSR1 (0.43) | — | |
| SCHEMBL13524364 | 0.79 | NPSR1 (0.42) | — | |
| SCHEMBL4247641 | 0.79 | NPSR1 (0.63) | — | |
| SCHEMBL29951331 | 0.79 | GLO1 (0.47) | — | |
| SCHEMBL11099235 | 0.79 | NPSR1 (0.42) | — | |
| SCHEMBL4254685 | 0.79 | NPSR1 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889133-B1 | 4-[[2-[[5-[1-(1H-INDOL-2-YL)-2-(PHENYL)-1-ETHEN-1-YL]-2-PYRIDINYL]OXY]ETHYL]AMINO]-2-BUTENAMIDE DERIVATIVES FOR THE TREATMENT OF ESTROGEN RECEPTOR POSITIVE BREAST CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12221432-B2 | Estrogen receptor antagonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-02-11 | — | — | US | disclosed |
| CN-118271341-A | Menin inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117430585-A | Estrogen receptor antagonists | 正大天晴药业集团股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-113166055-B | Estrogen receptor antagonists | 正大天晴药业集团股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-113620967-B | Alpha-mangostin derivative and preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2023-01-06 | — | — | CN | disclosed |
| US-20220033376-A1 | ESTROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-02-03 | — | — | US | disclosed |
| US-8835470-B2 | Mandelamide heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-8629282-B2 | Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130237566-A1 | HETEROCYCLIC COMPOUNDS AS S1P1 AGONISTS FOR THE TREATMENT OF AUTOIMMUNE AND VASCULAR DISEASES | BRISTOL=MYERS SQUIBB COMPANY | 2013-09-12 | — | — | US | disclosed |
| US-8404672-B2 | Substituted heterocyclic compounds | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20130045964-A1 | MANDELAMIDE HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-21 | — | — | US | disclosed |
| US-8354398-B2 | Substituted isoxazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110300165-A1 | SUBSTITUTED ISOXAZOLE COMPOUNDS | The Board of TRustees of the University of Illinoi University of Illinios (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-5717128-A | HEATING AN ESTER OF 2-HYDROXY-2-METHYL-3-BUTENOIC ACID WITH PHOSPHOROUS BROMIDE OR CHLORIDE; THEN WITH TRIALKYL ESTER OF PHOSPHOROUS ACID | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-10 | — | — | US | disclosed |